beta-amyloid ,

[Asn23]-beta-Amyloid (1-42), Iowa mutation, is a biologically active peptide with increased aggregation propensity and fibril toxicity. This mutation involves the substitution of Aspartic acid (Asp) at position 23 with Asparagine (Asn), contributing to autosomal dominant Alzheimer's Disease and associated with severe cerebral amyloid beta-protein angiopathy (CAA) due to a missense alteration at position 694 of the amyloid precursor protein (APP) gene.

Beta-Amyloid(1-14),mouse,rat is a 1 to 14 fragment of Amyloid-β peptide. This peptide is amino acids 1 to 14 fragment of Beta-Amyloid peptide.

Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.

Rutin (Quercetin 3-O-rutinoside), a flavonoid, has a variety of biological activities including antiallergic, anti-inflammatory, antiproliferative, and anticarcinogenic properties.

Deferoxamine Mesylate (DFOM) is an iron chelator and ferroptosis inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1α levels and induces apoptosis.

DAPT (LY-374973) is a γ-secretase inhibitor that inhibits total Aβ and Aβ42 (IC50=115/200 nM) and is orally active. DAPT is also a Notch inhibitor. DAPT induces cell differentiation, autophagy and apoptosis.

Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).

Trontinemab (RG6102) is a human IgG1-κ antibody selectively targeting Aβ precursor protein (APP) with transferrin receptor p90, CD71 (TFRC), inhibits amyloid production, and can be used to study neurological disorders such as Alzheimer's disease.

Colivelin is a neuroprotective peptide and activator of STAT3. Colivelin is a hybrid peptide synthesized to enhance the neuroprotective effects of humanin (HN).

Resveratrol (SRT 501) is a polyphenolic natural product, a plant antitoxin with antioxidant and chemopreventive activities. Resveratrol has a wide range of targets including COX, SIRT, LOC, etc. Resveratrol induces autophagy and apoptosis.

Nivegacetor(RG6289) is a selective and orally administrable γ-secretase regulator that can affect the production of amyloid-β in cerebrospinal fluid and can be used for the study of Alzheimer's disease.

CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM). CGP52411 blocks the toxic influx of Ca2+ ions into neuronal cells and dramatically inhibits and reverses the formation of β-amyloid Aβ42 fibril aggregates. CGP52411 can be used in studies about Alzheimer's diseases.

BMS 433796 is a γ-secretase inhibitor that demonstrates Aβ-lowering activity in a transgenic mouse model of Alzheimer's disease.

MK-3328 has a high affinity for β-Amyloid (IC50:10.5 nM), and can be used as a candidate PET ligand for clinical assessment of β-amyloid plaque load. MK-3328 is a potential treatment for Alzheimer's disease.

Rutin hydrate (Sophorin), a kind of glycoside, widely exists in many plants including citrus fruit.

PPI-1019 is an APP (β-amyloid A4) inhibitor for the treatment of neurological disorders and the study of Alzheimer's disease (AD).

Fenlean (FLZ) is a tyrosine kinase Src inhibitor, a synthetic cyclic derivative of squamous amide from Annona glabra, with cytoprotective activity, which protects tyrosine hydroxylase function in a chronic MPTP/prostaglandin-type mouse model of Parkinson's disease.Fenlean inhibits the production of Aβ in the mitochondria, which may be useful in the study of age-related macular degeneration and Parkinson's disease. and Parkinson's.

L-Clausenamide is an alkaloid extracted from the leaves of the yellow bark (Clausena lansium (Lour) skeels) and can be used to improve cognitive function. L-Clausenamide inhibits beta-amyloid (Aβ) toxicity and prevents the formation of neurofibrillary tangles by inhibiting tau phosphorylation. L-Clausenamide has neuroprotective activity and can be used to modulate stimuli triggered by Aβ25-35. L-Clausenamide can be used to study neurological disorders like Alzheimer's disease.

DSS30 is a P25/CDK5 inhibitor.DSS30 acts by inhibiting the phosphorylation of amyloid precursor protein cleaving enzyme 1 (BACEl), which reduces the secretion of β-amyloid (Aβ).DSS30 can be used for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease.

Compound 5936-0108 may has modulationg effect on β-Amyloid.

BI-1408 is a modulator potent of γ secretase (IC50: 0.04 μM for Aβ42).

Glutaminyl Cyclase Inhibitor 1, a glutaminyl cyclase inhibitor with an IC50 of 0.5 μM, can be utilized for studying neurological disorders.

K 01-162 binds and destabilizes AβO (β-amyloid), with an EC50 of 80 nM.

Ro 90-7501 is an amyloid β42 (Aβ42) protofibrillar and TPR-dependent PP5 inhibitor, a novel radiosensitizer for cervical cancer cells, which inhibits ATM phosphorylation, promotes apoptosis, and induces cell-cycle arrest. Ro 90-7501 also exhibits antiviral activity and potential anticancer activity by inhibiting ATM phosphorylation and DNA repair, and by inhibiting HCMV.